BioMarin Pharmaceutical offers $680M in cash, milestone payments for Dutch biotech Prosensa
November 24, 2014 at 06:32 AM EST
BioMarin Pharmaceutical will pay $680 million in cash for the Dutch biotech company Prosensa in a bid to strengthen its pipeline of genetic disorder treatments.
